MedPath

BRISTOL MYERS SQUIBB

🇺🇸United States
Ownership
-
Established
1989-01-01
Employees
30K
Market Cap
$97.5B
Website
https://www.bms.com/

Clinical Trials

1.7k

Active:130
Completed:1198

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:574
Phase 2:352
+3 more phases

Drug Approvals

11

SFDA:10
CIMA_AEMPS:1

Drug Approvals

REVIA COMPRIMIDOS RECUBIERTOS

Approval Date
Jul 14, 2025
CIMA_AEMPS

Clinical Trials

Distribution across different clinical trial phases (1333 trials with phase data)• Click on a phase to view related trials

Phase 1
574 (43.1%)
Phase 2
352 (26.4%)
Phase 3
320 (24.0%)
Phase 4
53 (4.0%)
Not Applicable
30 (2.3%)
phase_1_2
2 (0.2%)
Early Phase 1
1 (0.1%)
phase_2_3
1 (0.1%)

Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

Completed
Conditions
Advanced Melanoma
Interventions
Biological: Immunotherapy monotherapy
Drug: BRAF/MEK inhibitors
First Posted Date
2025-07-23
Last Posted Date
2025-07-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
678
Registration Number
NCT07079644
Locations
🇺🇸

Bristol Myers Squibb, Princeton, New Jersey, United States

A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors

Not Applicable
Not yet recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2025-07-22
Last Posted Date
2025-07-22
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
32
Registration Number
NCT07077434

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Not Applicable
Not yet recruiting
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
First Posted Date
2025-07-21
Last Posted Date
2025-07-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
470
Registration Number
NCT07076121
Locations
🇺🇸

Local Institution - 0142, Phoenix, Arizona, United States

🇺🇸

Local Institution - 0306, Springdale, Arkansas, United States

🇺🇸

Local Institution - 0157, San Francisco, California, United States

and more 255 locations

A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept

Active, not recruiting
Conditions
Myelodysplastic Syndromes
Interventions
First Posted Date
2025-07-20
Last Posted Date
2025-07-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
250
Registration Number
NCT07075406
Locations
🇺🇸

RTI Health Solutions, Research Triangle Park, North Carolina, United States

Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China

Active, not recruiting
Conditions
Myelodysplastic Syndromes
Interventions
First Posted Date
2025-07-18
Last Posted Date
2025-07-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
80
Registration Number
NCT07073690
Locations
🇨🇳

Zhijian Xiao, Tianjin, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 297
  • Next

News

Dispatch Bio Emerges with $216M to Develop Universal Solid Tumor Immunotherapy

Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.

BioNTech Chief Strategy Officer Ryan Richardson to Step Down After Seven-Year Tenure

Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.

Bristol Myers Squibb's Reblozyl Fails Primary Endpoint in Phase III Myelofibrosis Trial Despite Secondary Benefits

Bristol Myers Squibb's anemia drug Reblozyl failed to meet its primary endpoint of red blood cell transfusion independence in the Phase III INDEPENDENCE trial for myelofibrosis patients.

FDA Advisory Panel Rejects GSK's Blenrep Combination Therapies for Multiple Myeloma

FDA advisers voted 5-3 against approving GSK's Blenrep in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma patients.

Bristol Myers Squibb and Pfizer Launch Direct-to-Patient Eliquis Program with 40% Price Discount

Bristol Myers Squibb and Pfizer announced a new direct-to-patient purchasing option for Eliquis (apixaban) through their Eliquis 360 Support program, offering eligible patients a cash price more than 40% below the current $606 list price.

FDA Raises Eye Safety Concerns for GSK's Blenrep Ahead of Advisory Committee Review

The FDA has identified significant ocular toxicity concerns with GSK's Blenrep (belantamab mafodotin) ahead of a July 17 advisory committee meeting to review the drug's reintroduction to the U.S. market.

Insurance Disparities Widen Cancer Survival Gaps Despite Immune Checkpoint Inhibitor Advances

A new American Cancer Society study reveals that immune checkpoint inhibitors, while improving survival across all insurance groups, have widened survival disparities between uninsured patients and those with private insurance for advanced melanoma, lung, and kidney cancers.

AbbVie Acquires In Vivo CAR-T Developer Capstan Therapeutics for Up to $2.1 Billion

AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.

FDA Removes Regulatory Barriers for Bristol Myers Squibb's CAR T-Cell Therapies, Expanding Patient Access

The FDA eliminated Risk Evaluation and Mitigation Strategy (REMS) programs and reduced post-treatment monitoring from four weeks to two weeks for Bristol Myers Squibb's CAR T-cell therapies Breyanzi and Abecma.

FDA Approves Streamlined Access for Bristol Myers Squibb CAR T Cell Therapies

The FDA has approved label updates for Bristol Myers Squibb's CAR T cell therapies Breyanzi and Abecma, reducing patient monitoring requirements and removing Risk Evaluation and Mitigation Strategy (REMS) programs.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.